Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfredo Addeo

Showing results (21-30 of 224) with videos related to

Pageof 23
Sort By:
Mediastinum (Hong Kong, China)|July 14, 2022
The clinical fallout of organizational resilience in oncology during the pandemicAlfredo Addeo, Giuseppe L Banna
The Lancet. Oncology|July 12, 2016
LUX-Lung 7: is there enough data for a final conclusion?Massimo Di Maio, Alfredo Addeo
Journal of Thoracic Disease|October 30, 2018
The crucial role of predicting brain metastases development in non-small cell lung cancer patientsAlfredo Addeo, Giuseppe Luigi Banna
Translational Lung Cancer Research|November 6, 2018
PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?Alfredo Addeo, Giuseppe Luigi Banna
Translational Lung Cancer Research|November 6, 2018
PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?Alfredo Addeo, Giuseppe Luigi Banna
Case Reports in Hematology|March 28, 2013
A case of abdominal sarcoidosis in a patient with acute myeloid leukemiaVadsala Baskaran, Amanda Goodwin, Lavanya Athithan, et al.
Current Oncology Reports|November 4, 2021
The Role and Impact of Minimal Residual Disease in NSCLCDaniele Frisone, Alex Friedlaender, Alfredo Addeo
ESMO Open|July 6, 2019
New emerging targets in cancer immunotherapy: the role of TIM3Alex Friedlaender, Alfredo Addeo, Giuseppe Banna
Revue Medicale Suisse|May 17, 2023
Solange Peters, Alfredo Addeo, Matti Aapro
Frontiers in Oncology|June 24, 2020
Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 PandemicAlex Friedlaender, Chul Kim, Alfredo Addeo
Pageof 23

Showing results (21-30 of 224) with videos related to

Sort By:
Pageof 23
Mediastinum (Hong Kong, China)|July 14, 2022
The clinical fallout of organizational resilience in oncology during the pandemicAlfredo Addeo, Giuseppe L Banna
The Lancet. Oncology|July 12, 2016
LUX-Lung 7: is there enough data for a final conclusion?Massimo Di Maio, Alfredo Addeo
Journal of Thoracic Disease|October 30, 2018
The crucial role of predicting brain metastases development in non-small cell lung cancer patientsAlfredo Addeo, Giuseppe Luigi Banna
Translational Lung Cancer Research|November 6, 2018
PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?Alfredo Addeo, Giuseppe Luigi Banna
Translational Lung Cancer Research|November 6, 2018
PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?Alfredo Addeo, Giuseppe Luigi Banna
Case Reports in Hematology|March 28, 2013
A case of abdominal sarcoidosis in a patient with acute myeloid leukemiaVadsala Baskaran, Amanda Goodwin, Lavanya Athithan, et al.
Current Oncology Reports|November 4, 2021
The Role and Impact of Minimal Residual Disease in NSCLCDaniele Frisone, Alex Friedlaender, Alfredo Addeo
ESMO Open|July 6, 2019
New emerging targets in cancer immunotherapy: the role of TIM3Alex Friedlaender, Alfredo Addeo, Giuseppe Banna
Revue Medicale Suisse|May 17, 2023
Solange Peters, Alfredo Addeo, Matti Aapro
Frontiers in Oncology|June 24, 2020
Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 PandemicAlex Friedlaender, Chul Kim, Alfredo Addeo
Pageof 23